跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

How AI Is Changing Cancer Drug Discovery

1Why Cancer Drug Discovery Is So Hard2What AI Can and Cannot Do Here3Finding the Right Target4Designing Molecules with AI5Testing, Trials, and Real-World Impact6What's Next and What to Watch
Finding the Right Target

Turning Data into a Ranked Target List

2 / 3
Follow the arrows from left to right. Each box on the left is one kind of evidence: which genes are mutated, which proteins the tumor actually makes, how patients with those profiles fared, where the protein shows up in healthy tissue, and which proteins are known to work together. On its own, each of these is weak and noisy — a mutation might mean nothing, an expression reading might be a measurement artifact. The model's job is to weigh them together and produce the single ranked list on the right. Notice what the ranking does and does not claim. It says these candidates look most like targets that have worked before, and it attaches a confidence to each. It does not say the biology is confirmed. And notice the gap at the bottom: if a target was never measured in any of these datasets, it cannot appear in the ranking at all, no matter how important it is.
0:00 / 0:00

No single dataset says 'this is the target'. What researchers have instead is many partial views of the same disease, each noisy on its own. AI's contribution at this stage is to combine those views into one ranked list of candidate targets, so that limited laboratory time goes to the most promising few.

The inputs are heterogeneous. Tumor sequencing shows which genes are mutated, amplified, or deleted in patients. Gene expression measurements show which proteins the tumor is actually producing, which matters because a mutated gene that is never expressed is a poor target. Patient outcome data — how long people with a given tumor profile survived, and on which treatments — links molecular features to real consequences. Tissue studies show where a protein is present in the body, which speaks to side-effect risk. Databases of known biological relationships describe which proteins act together in the same pathway, so that a candidate with no drug yet can still be judged by its neighbors.

A model trained on these sources learns to score a candidate protein by how strongly its pattern of evidence resembles proteins that have already been successfully drugged, or how consistently it separates tumors that respond from those that do not. The output is a ranking with a confidence attached, not a verdict. Two things follow from that. First, the ranking is only as good as the data feeding it — a target that no cohort has ever been sequenced for will not surface, however important it is. Second, a high rank means 'worth testing', not 'correct'. The model has found a statistical resemblance to past successes; whether the biology actually behaves that way is still an open question that only an experiment can settle.

上一页2 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion